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ABSTRACT
Histone acetyltransferases (HATs) play a key role in
transcription control, cell proliferation and differen-
tiation by modulating chromatin structure; however,
little is known about their own regulation. Here we
show that expression of the viral oncoprotein SV40
T antigen increases histone acetylation and global
cellular HAT activities. In addition, it enhances
CREB-binding protein HAT activity and modulates
its transcriptional activity. Finally, we show that
inhibition of cellular histone deacetylases by tri-
chostatin A increases the SV40 infectivity rate.
These ®ndings highlight the importance of histone
acetylation in the regulation of the cell cycle by
oncoviral proteins.
INTRODUCTION
The packaging of the eukaryotic genome into chromatin
provides the means for compaction of the entire genome inside
the nucleus and restricts the access of many regulatory
proteins required for essential biological processes such as
replication, transcription, DNA repair and recombination (1).
To counterbalance the repressive nature of chromatin, several
factors are able to destabilise the nucleosome in order to
facilitate the interaction of proteins with nucleosomal DNA.
Recent studies have identi®ed that there are two types of
protein complexes capable of altering chromatin structure.
One of them utilises the energy coming from ATP hydrolysis
to alter the structure of nucleosomes (2). The second one
includes complexes that covalently modify histones (3,4) by
acetylation, methylation, phosphorylation, ubiquitination, etc.
Acetylation of the N-terminal tails of histones has been
known for many years to be a process correlating with
transcriptional activation (5,6), but the acetylation mechan-
isms and functions are just beginning to be revealed, thanks to
the identi®cation of the nuclear histone acetyltransferases
(HATs). CBP/p300 is a coactivator protein (7), involved in
both proliferative and differentiating pathways, which pos-
sesses HAT activity (8,9). CBP/p300 is ubiquitously ex-
pressed and regulates a broad spectrum of biological activities
such as differentiation, cell cycle control, apoptosis and
tumorigenesis. CBP/p300 is recruited to speci®c promoters
through interactions with sequence-speci®c activators, and in
turn recruits a second coactivator such as P/CAF (p300/CBP-
associated factor) (10). These activators include CREB (11),
c-Myb (12), MyoD (13), E2F1 (14), p53 (15) and nuclear
hormone receptors (16). All of these interactions are critical
for the execution of fundamental biological functions such as
cell differentiation, cell proliferation, apoptosis, etc.
The mechanism of the CBP/p300-mediated activation of
transcription is not clear, although we know that CBP/p300
contains multiple activation domains, it can contact the basal
transcription factors TATA box-binding protein (TBP) and
TFIIB (17), and its HAT domain is capable of activating
transcription (18). Moreover, other coactivators that complex
with CBP/p300, such as P/CAF, activator of retinoic acid
receptor (ACTR) (19) and steroid receptor coactivator-1
(SRC-1) (20), themselves contain intrinsic nucleosomal HAT
activity.
SV40 large T antigen is a multifunctional viral oncoprotein
implicated in a wide range of cellular processes including
transcriptional activation and repression, blockade of differ-
entiation, stimulation of the cell cycle and cell transformation
(21). The SV40 virus gains control of the cell through complex
interactions between the viral oncoproteins and various
intracellular proteins (22) involved in cell control and
regulation of transcription, such as p53 (23,24), pRb and
Rb-related proteins p107 and p130 (25±28), and CBP/p300
(29±32).
T antigen interacts with the p300 unphosphorylated but
ubiquitinated form of the protein (30,31) and with CREB-
binding protein (CBP) (30). In contrast to T antigen, the
adenovirus early expression product E1A interacts with both
phosphorylated and unphosphorylated forms of p300. Both
T antigen and E1A affect transcription levels of the cAMP-
responsive promoter that is modulated in vivo by p300 in
REV2 cells. CBP/p300 also interacts with E1A protein and
abrogates CBP/p300-mediated transcriptional activity (33).
The mechanism by which this repression occurs is not yet
clear. It could occur by sequestration of CBP/p300 away from
the promoter; alternatively, E1A may displace the CBP/p300-
associated factor, which is required for ef®cient activation of
transcription. Another possibility (34,35) it is that E1A
inhibits the HAT activity of CBP/p300 and P/CAF.
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However, another study has shown an activation of CBP HAT
activity by E1A (36).
Since T antigen also interacts with CBP (30) but very little
is known about the consequences on CBP activity, we asked
whether T antigen is able to modulate the HAT activity of host
cells as well as the CBP coactivator. We show that T antigen
expression increases global histone acetylation and CBP HAT
activity. Moreover, the T antigen can stimulate HAT-mediated
CBP transcriptional activity in a Gal4-hsp70 promoter.
Finally, we show that inhibition of cellular histone deacety-
lases (HDACs) increases the SV40 infectivity rate.
MATERIALS AND METHODS
Constructs
pSG5-T antigen plasmid was a gift of Dr J. DeCaprio. pSG5-T
antigen DCBP contains a 379 bp deletion. It was made by
partial digestion of the pSG5-T antigen plasmid with NsiI
restriction endonuclease, posterior digestion of the puri®ed
6.3 kb fragment with PstI restriction endonuclease and
religation of the puri®ed 5.9 kb fragment. pCDNA3Gal4-
HAT, pCDNA3Gal4-HAT-CBP2 and pCDNA3Gal4(DBD)
constructs have been described elsewhere (18) and were
kindly provided by Dr T. Kouzarides. The Gal4-hsp70-b-gal
reporter was supplied by Dr J. Bernues. The pCMV-DP1
construct has been described elsewhere (14) and was kindly
provided by Dr D. Trouche.
Cell culture, transfections and reporter gene assay
CV1 and CV1COS cells were maintained in Dulbecco's
modi®ed Eagle's medium (DMEM) with 10% foetal calf
serum (FCS) and grown at 37°C, 5% CO2. G1 cell synchron-
isation was achieved by removal of FCS from the medium
(DMEM) for 36 h and collection of cells 8 h after addition of
FCS to the medium.
Cells were transfected by a standard calcium phosphate co-
precipitation (for b-galactosidase assays) or using a Jet-PEI
Kit (GenyCell) (for HAT assays; by using this method, ~80%
of the cells were transfected, as we determined by ¯uorescence
after co-transfection with pCDNA3-GFP) with 0.1±2 mg (as
indicated) of either expression vector and 2 mg of
b-galactosidase reporter plasmid. The cells were washed
after 14 h and harvested 36 h after transfection. After that, they
were washed once in phosphate-buffered saline (PBS). For
b-galactosidase assay, cells were lysed in 150 ml of
b-galactosidase lysis buffer (Promega) for 20 min at room
temperature. Supernatants were clari®ed by centrifugation
(2 min, 12 000 g) and 30 ml were mixed with 270 ml of
b-galactosidase assay solution (Promega) and analysed at
OD420.
Cell extract preparation, histone extraction and
estimation of the protein content
Histones were extracted by overnight treatment of whole cells
with 0.25 M HCl at 4°C under rotation. After centrifugation at
12 000 g for 10 min at 4°C, histones were precipitated by cold
acetone and resuspended in SDS-protein loading buffer. Total
cell extracts were prepared as follows: cells were lysed in 1 ml
of buffer A (50 mM Tris±HCl, pH 8, 150 mM NaCl, 0.5%
NP-40, 10 mg/ml of aprotinin and leupeptin, 1 mM
phenylmethylsulfonyl ¯uoride, 50 mM NaF and 10 mM
Na2-b-glycerophosphate) by keeping the cells on ice for
20 min, and cell debris was removed by centrifugation at
12 000 g for 10 min at 4°C. Estimation of the protein content
was done by using the `Bio-Rad protein Assay reagent'
following the the manufacturer's instructions.
Immunoprecipitations and western analysis
Immunoprecipitations and western blot analysis were per-
formed as described elsewhere (37) with modi®cations: 10-cm
dishes of CV1 cells and transfected CV1 cells with the
indicated amount of each expression vector were harvested
36 h post-transfection. Cells were lysed in 1 ml of buffer A by
keeping them on ice for 20 min, debris was removed by
centrifugation and the cleared lysate was subjected to
immunoprecipitation with 2 mg of CBP antibody for 3 h at
4°C with rotation. A 15 ml aliquot of protein A/protein
G±Sepharose beads (a 50:50 mix) was then added and
incubated overnight at 4°C under rotation. The immune
complexes were pelleted by gentle centrifugation and washed
three times with 1 ml of lysis buffer B (20 mM Tris±HCl,
pH 7.5, 100 mM NaCl, 1 mM EDTA and 0.5% NP-40). After
the ®nal wash, the buffer was aspirated and the antibody beads
were either resuspended in loading buffer for SDS±PAGE to
be analysed by western blot or used in the HAT assay as
described below. Western blotting was performed using
standard procedures and visualised using an enhanced
chemiluminescence kit (Amersham). The antibodies used
were: whole antiserum anti-T antigen (a gift from Dr J.
DiCaprio), af®nity-puri®ed anti-CBP, A22 (Santa Cruz
Biotechnology) at 1:1000 dilution, af®nity-puri®ed anti-
hemagglutinin (HA; Upstate Biotechnology) at 1:1500 dilu-
tion, and whole antiserum anti-acetyl-lysine, antibody 193
(abcam) at 1:100 dilution; this antibody was raised against
chemically acetylated human histone H4 and reacts with e-
acetylated lysines of the four core histones.
HAT and IP-HAT assays
IP-HAT assays were performed as described elsewhere (8,18).
Basically, extracts from CV1, CV1COS or transfected CV1
cells were made using 500 ml of buffer A. The lysis mixture
was incubated on ice for 20 min and cleared by centrifugation
at 12 000 g for 10 min at 4°C. A 2 mg aliquot of CBP antibody
was used to precipitate the CBP for 3 h at 4°C with rotation,
then 15 ml of protein A/protein G±Sepharose beads (a 50:50
mix) were added and incubated overnight at 4°C under
rotation. The immune complexes were pelleted by gentle
centrifugation and washed three times with 1 ml of buffer B.
After the ®nal wash, the buffer was aspirated down to 30 ml
and the liquid HAT assay was done as described (8). Puri®ed
chicken erythrocyte histones (Sigma) were use as substrate.
Viral infection
Subcon¯uent CV1 cells were infected with the SV40 virus as
described in Su and DePamphilis (38), and grown for
8±10 days in DMEM with 5% FCS, 0.9% agar and 75,
100 or 150 nM Trichostatin A (TSA). After 8±10 days, they
were stained with neutral red and the lysis colonies were
counted after 24±48 h.
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Bioinformatics tools
Sequence searches were done using the PSI-BLAST pro-
gram (39) with default parameters. The multiple sequence
alignment for the E1A family was obtained from the Pfam
database (40), with accession number PF02703.
RESULTS
T antigen expression affects cellular histone acetylation
Several independent ®ndings indicate that HATs and HDACs
play an important role in cell cycle regulation, suggesting that
these enzymes represent likely targets of viral oncoproteins
that deregulate the cell cycle.
To test whether global HAT activities are modi®ed by the
SV40 regulatory oncoprotein T antigen, we analysed the HAT
activity of cells expressing (CV1COS cell line) and not
expressing (CV1 cell line) the SV40 T antigen, by an in vitro
HAT assay. To that end, total cellular extracts from CV1 and
CV1COS were prepared, the total protein amount was
adjusted and the extracts were incubated with puri®ed chicken
erythrocyte core histones and [3H]acetyl-CoA. The level of
histone acetylation was analysed by ¯uorography (Fig. 1A)
and quanti®ed in a scintillation counter (Fig. 1B). The global
HAT activity was ~2.3 fold (1.9±2.5) higher in T antigen-
expressing cells (Fig. 1B). To con®rm this result, we
transfected the T antigen on CV1 cells (80% of the cells
were transfected), adjusted the total protein amount in the cell
extracts and determined the HAT activity of T antigen-
transfected and non-transfected cells by liquid HAT assay.
The results in Figure 1C show an increased global HAT
activity after T antigen expression.
We then aimed at elucidating whether the histones from
cells expressing the T antigen were more acetylated than those
from non-expressing cells. To this end, histones from both
CV1 and CV1COS cells were prepared by acid extraction and
their level of acetylation was analysed by western blot using
an antibody raised against chemically acetylated human
histone H4 which reacts with e-acetylated lysines of the four
core histones (abcam, ab 193) (41). The results in Figure 2
show that the acetylation level of H3, H2A/B and H4 in T
antigen-expressing cells (CV1COS) was 5-fold higher than in
non-expressing cells (CV1). The acetylation levels of H3 and
H2A/B increased more than H4. In particular, the acetylation
of H2A/B was as high as H4 acetylation, suggesting that T
antigen expression could lead to acetylation of all lysines on
H2A/B histones tails in vivo. One reason for such a high
H2A/B acetylation could be the fast DNA replication after
viral infection. Alternatively, changes in speci®city of cellular
HAT after viral infection could account for the observed
histone acetylation pattern change. According to that, it would
be interesting to check whether the same increase in H2A/B
acetylation occurs after infection by other DNA viruses.
These results support that T antigen expression leads to a
global increase of HAT activities and histone acetylation
level.
T antigen expression affects CBP HAT activity
Given that T antigen binds the third ®nger on the CBP
molecule, very close to the HAT domain, and that T antigen
expression increases cellular histone acetylation (see above),
we next determined whether T antigen expression affects the
intrinsic CBP HAT activity. Using an IP-HAT assay approach,
CBP from cells expressing or not expressing the T antigen was
immunoprecipitated and the HAT activity within the im-
munopellet assessed. Figure 3A shows that CBP HAT activity
in cells expressing T antigen was higher (2.3-fold increase)
than in cells lacking the T antigen, especially in cells arrested
in G1 by serum starvation (4.2-fold increase) (Fig. 3B).
Similar amounts of CBP were immunoprecipitated in CV1 and
CV1COS cells, as shown in the bottom panels of Figure 3A
Figure 1. Expression of T antigen increases cellular global HAT activity.
(A) Increasing amounts (0.1±10 mg) of CV1 and CV1COS whole-cell
extracts were tested for their ability to acetylate free histones in an in vitro
HAT assay (8). Basically, whole-cell extracts were incubated with puri®ed
chicken erythrocyte histones (Sigma) and [14C]acetyl-CoA at 30°C for
30 min. The level of histone acetylation was analysed in an 18% polyacryla-
mide gel and revealed by ¯uorography. (B) To quantify the HAT activity
present in CV1 and CV1COS cells, increasing amounts (0.1±10 mg) of CV1
and CV1COS whole-cell extracts were tested for their ability to acetylate
free histones in a standard liquid HAT assay. HAT activity is expressed as
radioactivity (c.p.m.) associated with 3H-labelled acetylated core histones.
(C) CV1 cells were transfected with 10 mg of pSG5-T antigen and
pCDNA3-GFP using a Jet-PEI Kit (GenyCell). Around 80% of the cells
were transfected, as determined by ¯uorescence. Whole-cell extracts from
transfected and non-transfected cells were prepared and used in a liquid
HAT assay as in (B). The global HAT activity associated with cells not
expressing and expressing T antigen is expressed as radioactivity (c.p.m.)
associated with 3H-labelled acetylated core histones.
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and B. Western blot analysis revealed no differences in the
amount of CBP in the two cell lines (Fig. 3C). To investigate
whether T antigen was directly responsible for this increase in
CBP HAT activity in vivo, we introduced a deletion at the
C-terminal CBP-binding region on the T antigen (amino acids
401±536) protein which rendered the T antigen unable to bind
CBP (Fig. 3D, bottom panel); it was named DCBP. We then
transfected the wild-type T antigen and the mutant (DCBP) T
antigen on CV1 cells (~80% of the cells were transfected), and
afterwards we prepared whole-cell extracts, adjusted the total
protein amount in transfected and non-transfected cell extracts
and determined CBP HAT activity, as previously described.
CBP HAT activity showed a reproducible increase after
expression of the wild-type T antigen (Fig. 3D) but not of the
DCBP T antigen. The expression level of wild-type and DCBP
T antigen after transfection on CV1 cells was similar (Fig. 3D,
top panel). The con®rmation of this result in vitro, by using
recombinant puri®ed proteins, was not possible due to the low
level of T antigen expression in Escherichia coli.
Altogether, these data suggest that the oncoprotein T
antigen modulates cellular HAT activities and in particular
CBP HAT activity.
Given that T antigen affects CBP HAT activity, we next
tested whether the CBP speci®city for core histones is altered
by T antigen expression. To do this, CBP from CV1 and
CV1COS cells was immunoprecipitated using antibodies
against CBP and HA (as a control antibody) and the HAT
activity associated with the immunoprecipitates was analysed
by ¯uorography (Fig. 4A), quanti®ed by densitometry in a
Molecular Dynamics machine (Fig. 4B, top panel) and
normalised relative to the value in CV1 cells (value: 1)
(Fig. 4B, bottom panel). The results in Figure 4A and B
con®rm an increased CBP HAT activity on CV1COS cells and
show no modi®cation of the CBP speci®city for core histones
by the T antigen.
T antigen modulates CBP HAT-mediated activation
Since T antigen affects CBP HAT activity, we aimed at
determining whether it also modulates the transcriptional
activity mediated by the CBP HAT domain. To avoid
interference by other CBP domains, in particular the C-
terminus (capable of binding to other proteins such as P/CAF
and SRC-1, which also carry their own HAT activity), we
separated the CBP HAT and CBP2 (the CBP third ®nger,
where the T antigen binds CBP) domains (HAT-CBP2) from
the rest of the molecule and fused them with the Gal4 DNA-
binding domain (Gal4-HAT-CBP2). Previous results (18)
have shown that a region of CBP, encompassing the previ-
ously de®ned HAT domain, can stimulate transcription when
tethered to a promoter. This stimulatory effect is dependent on
HAT activity. The activation capacity of the CBP HAT
domain increases by the fusion of the CBP2 domain (which
harbours the binding site for a variety of regulatory transcrip-
tion factors: E2F and c-Fos).
First, we measured the transcriptional activity mediated by
the Gal4-HAT-CBP2 domains on the hsp70 promoter, which
contain ®ve Gal4-binding sites, by transient transfection, and
then we examined whether wild-type and DCBP T antigen
affect the transcriptional activity of the Gal4-HAT-CBP2. The
results in Figure 5 show that Gal4-HAT-CBP2 activates the
hsp70 promoter. We also observed that T antigen ef®ciently
stimulated the ability of HAT-CBP2 to activate the hsp70
promoter (Fig. 5A) in a speci®c manner because, when
expressing another protein (DP1), no effect was found
(Fig. 5A). This T antigen coactivation is dependent on CBP
binding because the mutant T antigen (DCBP) was also
defective in coactivation (Fig. 5B). To con®rm this result, we
have also used a CBP construct that contains only the HAT
domain and lacks the CBP2 region (T antigen-binding region)
fused to the Gal4 DNA-binding domain (Gal4-HAT). This
construct is still able to activate transcription, but is a very
weak activator (18). The results in Figure 5C show that the
coactivating effects of T antigen on the transcriptional activity
CBP HAT (which has lost the T antigen-binding site) are
substantially reduced.
Altogether, the results from the transfection experiments
strongly suggest that T antigen binding to CBP (through the
CBP2 region) modulates the transcriptional activity mediated
by the CBP HAT domain on the hsp70 promoter.
The histone deacetylase inhibitor, TSA, increases the
SV40 infectivity rate
Our previous results show that expression of the T antigen
leads to an increase in cellular HAT activity, suggesting that
T antigen oncoprotein targets HATs and HDACs to deregulate
the cell cycle and/or to regulate viral and cellular genes. We
next tested whether inhibition of HDAC activity could affect
viral growth and infectivity. CV1 cells were infected with
SV40 and maintained in the presence or absence of increasing
nanomolar concentrations of the potent HDAC inhibitor TSA.
After 7±10 days, the cells from duplicate dishes were stained
with neutral red and viral lysis plates were counted. In the
presence of TSA, the growth rate of SV40 was clearly higher
and more lysis plates were generated (3- to 6.5-fold) than in
the absence of the HDAC inhibitor (Table 1). In addition, after
TSA treatment, lysis plates appeared earlier (2±4 days) than in
non-treated cells. Similar growth rates were observed with
75±100 nM TSA (above this concentration, cell death started
to appear) and at various infection multiplicities (from 4 to
40 p.f.u.).
Figure 2. Total histones were prepared by acid extraction from CV1 and
CV1COS cells and their acetylation levels were analysed by western blot
using an antibody that recognises acetylated lysines (ab 193; abcam)
(bottom panel). The top panel shows the Ponceau staining of the gel as a
histones level control. Histones (H3, H2A/B and H4) are indicated by
arrows.
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DISCUSSION
The SV40 virus requires cellular proliferation for its own
replication. Therefore, one of its regulatory proteins, the T
antigen, has evolved to steer cells through the cell cycle. To
transform mammalian cells, T antigen needs to interact with
three different proteins: one that includes proteins from the
Rb-pocket family (resulting in the loss of the ability to
suppress growth), p53 and proteins from the CBP/p300 family
of coactivators (which facilitate cellular transformation). Here
Figure 3. CBP HAT activity increased after T antigen expression. (A) An equal amount of total protein of CV1 and CV1COS whole-cell extracts was
precipitated with anti-CBP antibody and the immunocomplexes were tested for their ability to acetylate free histones in a liquid HAT assay. The presence of
T antigen and CBP in the immunoprecipitates in CV1 and CV1COS cells was tested by western blot using anti-T antigen and anti-CBP antibodies,
respectively (shown in the bottom part). The data are the average of at least four independent experiments. (B) CV1 and CV1COS cells were serum starved,
and the HAT activity analysis was performed as in (A). (C) Increasing amounts of CV1 and CV1COS whole-cell extracts were loaded onto a 7%
polyacrylamide gel, and the amounts of CBP in the two cells lines were determined by western blot using anti-CBP antibody. (D) CV1 cells were transfected
with 10 mg of pSG5-T antigen (TAg), pSG5-T antigenDCBP (TAgDCBP) antigen and pCDNA3-GFP using a Jet-PEI Kit (GenyCell). Around 80% of the
cells were transfected by this method, as con®rmed by ¯uorescence. Whole-cell extracts from transfected and non-transfected cells were prepared. An equal
amount of total protein was precipitated with anti-CBP antibody and the immunocomplexes tested for their ability to acetylate free histones in a liquid HAT
assay (top part) and for the presence of CBP and T antigen by western blot using anti-CBP and anti-T antigen antibodies, respectively (bottom part). The
expression levels of TAg and TAgDCBP after transfection were determined by western blot using anti-T antigen antibody (top part). The data are the average
of at least three independent transfections.
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we have shown that the interaction of T antigen with CBP
modulates CBP activities. T antigen expression increases CBP
HAT activity, which is higher when the cells have been serum
starved. As reported elsewhere, CBP HAT activity is modu-
lated by another viral protein, E1A, although there is
considerable controversy in the literature: Ait-Si-Ali et al.
(36) have shown that E1A increases CBP HAT activity to a
level similar to that obtained in this study, whereas
Chakravarti et al. (35) have proposed that CBP and P/CAF
HAT activities are inhibited through interaction with E1A, as
con®rmed by Hamamori (34). On the other hand, work from
Kouzarides' lab shows that E1A does not alter P/CAF HAT
activity in vitro or in vivo (42). In the case of T antigen, ours is
the ®rst report showing a modulation of CBP HAT activity,
which supports the hypothesis that cellular HAT activities are
a direct target for acetyltransferase regulation by viral
oncoproteins.
We have also shown that global histone acetylation status
increased after T antigen expression. We believe that this
global increase is mainly a consequence of the higher global
HAT activity (as shown in Fig. 1), or due to the regulation of
HAT accessibility to substrate. However, we cannot exclude
some indirect effects due to the T antigen-induced transform-
ation process.
What could be the meaning of a global increase in the
histone acetylation level? Treissman et al. (43) have shown
that H4 hyperacetylation can occur even when transcription is
blocked by actinomycin D, suggesting that global histone
hyperacetylation can occur when transcription is not active.
Transcriptional HATs also play an apparent non-transcrip-
tional role in establishing the total genomic balance of
acetylation (44±46). Global acetylation may thus represent a
general response of the cells to a stimulus, in this case a viral
oncoprotein, which may alter the threshold level to trigger
transcription. On the other hand, the general increased histone
acetylation level may be due merely to the addition effects of
the locally higher acetylation from T antigen-regulated
promoters.
E1A and other CBP/p300-binding proteins may interact
with the CBP TRAM motif through the FPESDLIL sequence
(47). We searched the SV40 T antigen for this motif by
sequence comparison. FPESLIL aligned with a similar peptide
in the SV40 T antigen. However, the match falls in an SV40 T
antigen region that does not bind CBP. In addition, the BLAST
program (48) provides even better identities for the
FPESDLIL sequence to proteins that have not been described
as CBP partners and show very divergent functions. These two
facts suggest that the observed match in the SV40 T antigen is
fortuitous. By comparing the whole E1A and SV40 T antigen
sequences, we found a certain percentage of identity between
two sequence stretches, which do not correspond to the
binding site of any of the proteins. Finally, we looked for the
pattern FX (D, E) XXXL, identi®ed by E1A and other third
®nger CBP-interacting proteins (p53 and E2F), in the SV40 T
antigen, but did not ®nd it. This may be due to the fact that the
E1A pattern was derived from a reduced set of protein
sequences. When more sequences become available, the
pattern may not be as conserved as it seemed from the original
data. In the Pfam (39) alignment for the E1A family of
proteins, there are changes in all the pattern positions (Fig. 6),
even in those that had been considered ®xed. The SV40 T
antigen and E1A could thus have a structurally similar binding
surface to CBP, but corresponding to a degenerate sequence
pattern. A second option could be that the SV40 T antigen has
Figure 4. CBP speci®city for core histone does not change after T antigen expression. An equal amount of total protein of CV1 and CV1COS whole-cell
extracts was precipitated with anti-CBP and HA antibodies and the immunocomplexes tested for their ability to acetylate free histones in an in vitro HAT
assay. (A) Fluorograph showing the HAT activity of CBP from CV1 and CV1COS cells. (B) The bands corresponding to H3, H2A/B and H4 histones were
quanti®ed by densitometry using a Molecular Dynamics machine (top panel). The acetylation levels of H3, H2A/B and H4 in CV1COS cells were normalised
relative to the acetylation levels in CV1 cells (value 1) (bottom panel). The acetylation level of the four core histones increased in CV1COS cells between
5- and 6-fold relative to the acetylation level of CV1 cells.
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Figure 5. T antigen activates CBP HAT-mediated activation on the hsp70 promoter. (A) CV1 cells were transfected with 2 mg of the Gal4-hsp70-b-gal
reporter, 2 mg of Gal4 DNA-binding domain (DBD) or Gal4-HAT-CBP2, and increasing amounts (0.1±2 mg) of pSG5-T antigen, pCDNA3-DP1 or the empty
vector. Whole-cell extracts were used in the b-galactosidase assay. The activity derived from the Gal4-hsp70-b-gal reporter plus the pcDNA3-Gal4(DBD) was
normalised to 1.0, and the other activities are expressed relative to this. The data are an average of at least six independent transfections. (B) T antigen
activates CBP HAT-mediated activation in a CBP binding-dependent manner. CV1 cells were transfected with 2 mg of the Gal4-hsp70-b-gal reporter, 2 mg of
Gal4 DBD or Gal4-HAT-CBP2, and increasing amounts (0.1±2 mg) of pSG5-T antigen DCBP or the empty vector. Whole-cell extracts were used in the
b-galactosidase assay. The activity derived from the Gal4-hsp70-b-gal reporter plus the pCDNA3-Gal4(DBD) was normalised to 1.0, and the other activities
are expressed relative to this. The data are an average of at least four independent transfections. (C) CV1 cells were transfected with 2 mg of the
Gal4-hsp70-b-gal reporter, 2 mg of Gal4 DBD or Gal4-HAT, and 0.5 and 2 mg of pSG5-T antigen or the empty vector. The transcriptional activity of the
hsp70 promoter was determined as above. The data are an average of at least three independent transfections.
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a well-de®ned sequence pattern, responsible for the binding to
CBP, which is different from FX (D, E) XXXL. This would
suggest the existence of a different binding mechanism for
CBP/p300.
Our results point to the key role of the acetylase and
deacetylase activities in viral growth promoted by T antigen.
They show that a viral oncoprotein may manipulate gene
expression by interfering with HAT chromatin-modifying
enzymes. These observations highlight the relevance of
acetylation/deacetylation pathways in the regulation of cell
proliferation and viral infection.
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